THERAPY OF THYROID DISEASE WITH 131I• Silberstein et al. 1633 patients throughout
the United States. Existing practice guidelines will be reviewed for revision or renewal, as …

90 Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic agent recently approved for
the treatment of relapsed or refractory low-grade, follicular, or CD20+ transformed non-…

… An important part of this work was to use Y91data (Marcus and Lengemann, '62) previously
… ported and discussed in the paper based on use of yttrium-91 (Marcus and Lengemann, '62). …

In calculations of absorbed doses from radioactive patients, the activity distribution in such
patients is generally assumed to be an unattenuated point source and the dose to exposed …

MATERIALSAND METHODS To be able to label VIP with@ Tc, the peptidewas modified at
the C-terminus by the addition of 5 amino acids. Of these, Gly@ Â-(D)-Ala31-Gly32-Gly33 (…

Patients who are candidates for samarium-153 ethylenediaminetetramethylenephosphonic
acid (Sm-153 EDTMP) therapy often receive monthly infusions of pamidronate disodium or …

Medical licensees are required to comply with US Nuclear Regulatory Commission (NRC)
regulations pertaining to the release of patients administered radioactive material. However, …

On February 9, 2015, I submitted a petition to the US Nuclear Regulatory Commission (NRC)
to reject the linear-no threshold (LNT) hypothesis and ALARA as the bases for radiation …

Platelet accumulation on carbon-lined (CL) and high-porosity (HP) polytetrafluoroethylene (PTFE)
grafts was investigated in vivo. In experiment 1, 20 CL grafts and 20 control PTFE …

… Freeman, Albert Einstein College of Medicine, Bronx, NY; Ian Jong, Monash Health,
Melbourne, Victoria, Australia; Kalevi Kairemo, Docrates Cancer Center, Helsinki, Finland; …